|
End-of-day quote
Buenos Aires S.E.
11/08/2026
|
5-day change | 1st Jan Change | ||
| 62,900.00 ARS | -1.83% |
|
+2.36% | -10.84% |
| 06:43pm | Octave slid after earnings report, OMXS30 index down 0.2% | FW |
| 05:13pm | AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Combo Gets Approval in China | MT |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 248,167 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -13.77% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 267,493 | 259,826 | 251,315 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -14.04% | -2.87% | -3.28% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.5x | 17.9x | 15.5x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.6x | 4.09x | 3.47x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.2x | 1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.92x | 3.71x | 3.48x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.23x | 3.89x | 3.52x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12x | 10.6x | 9.39x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.7x | 11.2x | 9.83x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.4x | 20x | 17.4x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.52% | 4.99% | 5.75% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.325 | 3.528 | 3.662 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.08% | 2.2% | 2.29% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.807 | 8.959 | 10.31 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.6% | 39.4% | 35.5% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,251 | 66,854 | 71,304 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,272 | 24,397 | 26,752 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,049 | 23,267 | 25,568 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,070 | 13,716 | 15,668 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,326 | 11,659 | 3,147 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 160.00 | 160.00 | 160.00 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 A | 2/9/23 A | 2/8/24 A | 2/6/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.45x | 12.59x | 25.62x | 0.57% | 1,083B | |
| 28.9x | - | - | 2.07% | 626B | |
| 31.93x | 7.43x | 15.44x | 2.74% | 442B | |
| 20.56x | 4.87x | 12.07x | 2.71% | 363B | |
| 22.02x | 5.7x | 14.21x | 2.82% | 295B | |
| 20.5x | 4.23x | 12.01x | 2.08% | 248B | |
| 25.99x | 6.83x | 12.15x | 2.43% | 224B | |
| 13.93x | 4.99x | 10.37x | 3.65% | 210B | |
| -42.16x | 6.03x | 34.04x | 2.43% | 168B | |
| Average | 17.35x | 6.58x | 16.99x | 2.39% | 406.57B | |
| Weighted average by Cap. | 24.65x | 8.25x | 18.71x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
